HLS Therapeutics Inc. (HLS) Q3 Revenue Rose 5%; Net Loss Narrowed to $2.2M
Q3 2026 revenue rose 5% year over year; Adjusted EBITDA was $5.0M versus $4.9M, and net loss narrowed to $2.2M from $3.9M. HLS refined 2026 targets within previously guided ranges and expects revenue and Adjusted EBITDA growth to step up in 2027.Material DetailsContext by AI AnalystThis is a quarte…